Drug Trial Radar · NCT07336472
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
360
Planned (sponsor's estimate)
Start
Sep 30, 2026
Primary completion
Jun 30, 2027
Study completion Sep 30, 2028
Sponsor
- Lead sponsor
- Fortvita Biologics (USA)Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 54\~360 subjects, and a phase 2 stage to explore efficacy, safety and tolerability of IBI3003 at RP2D in multiple myeloma
Conditions
- Multiple Myeloma
Interventions
IBI3003Drug
Participants will receive IBI3003 treatment until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, or end of the study or for a maximum of 24 months, whichever occurs first.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AEs)Time frame: Up to 30 days post last dose
- Dose limiting toxicities (DLTs)Time frame: Up to 28 days post first dose
- ORRTime frame: up to 24 months
- To determine the maximum tolerated dose (MTD) and the recommended Phase 2 Dose (RP2D) of IBI3003Time frame: up to 24 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Honor Health
Scottsdale, Arizona · Active not recruiting
City of Hope - Duarte
Duarte, California · Recruiting
City of Hope - Lennar
Irvine, California · Recruiting
Emory
Atlanta, Georgia · Active not recruiting
Memorial Sloan Kettering
New York, New York · Recruiting
MD Anderson
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.